Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tenax Therapeutics, Inc.

Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Set to Join Russell Microcap® Index
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
From Tenax Therapeutics, Inc.
Via Business Wire
Tickers TENX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.